

Indian Journal of Pharmaceutical Sciences

Scientific Publication of the Indian Pharmaceutical Association

Indexed in Ind MED, EMBASE/Excerpta Medica, International Pharmaceutical Abstracts, Chemical Abstracts.

Volume 69

Number 5

September-October 2007

CONTENTS

REVIEW ARTICLES

- Recent Trends in Drug-Likeness Prediction: A Comprehensive Review of *In Silico* Methods**
R. U. KADAM AND N. ROY 609-615
- Biodegradable Polymers: Which, When and Why?**
V. B. KOTWAL, MARIA SAIFEE, NAZMA INAMDAR AND KIRAN BHISE 616-625

RESEARCH PAPERS

- Strong Cation Exchange Resin for Improving Physicochemical Properties and Sustaining Release of Ranitidine Hydrochloride**
S. KHAN, A. GUHA, P. G. YEOLE, AND P. KATARIYA 626-632
- Novel Co-Processed Excipients of Mannitol and Microcrystalline Cellulose for Preparing Fast Dissolving Tablets of Glipizide**
S. JACOB, A. A. SHIRWAIKAR, A. JOSEPH, K. K. SRINIVASAN 633-639
- Formulation and Optimization of Directly Compressible Isoniazid Modified Release Matrix Tablet**
M. C. GOHEL, R. K. PARIKH, M. N. PADSHALA, K. G. SARVAIYA AND D. G. JENA 640-645
- Effect of Casting Solvent and Polymer on Permeability of Propranolol Hydrochloride Through Membrane Controlled Transdermal Drug Delivery System**
T. E. G. K. MURTHY AND V. S. KISHORE 646-650
- Preparation of Mucoadhesive Microspheres for Nasal Delivery by Spray Drying**
MAHALAXMI RATHANANAND, D. S. KUMAR, A. SHIRWAIKAR, RAVI KUMAR, D. SAMPATH KUMAR AND R. S. PRASAD 651-657
- Effect of Polymers on Crystallo-co-agglomeration of Ibuprofen-Paracetamol: Factorial Design**
A. PAWAR, A. R. PARADKAR, S. S. KADAM AND K. R. MAHADIK 658-664
- Synthesis and Antimicrobial Evaluation of Some Novel 2-Imino-3-(4'-carboxamido pyridyl)-5-Arylidene-4-Thiazolidinones and their Brominated Derivatives**
P. MISHRA, T. LUKOSE AND S. K. KASHAW 665-668
- Measurement of Urine and Plasma Oxalate with Reusable Strip of Amaranthus Leaf Oxalate Oxidase**
NISHA SHARMA, MINAKSHI SHARMA, V. KUMAR AND C. S. PUNDIR 669-673

SHORT COMMUNICATIONS

- Simultaneous HPLC Estimation of Omeprazole and Domperidone from Tablets**
LAKSHMI SIVASUBRAMANIAN AND V. ANILKUMAR 674-676
- Isolation and Evaluation of Fenugreek Seed Husk as a Granulating Agent**
AMELIA AVACHAT, K. N. GUJAR, V. B. KOTWAL AND SONALI PATIL 676-679
- Synthesis and *In Vitro* Efficacy of some Halogenated Imine Derivatives as Potential Antimicrobial Agents**
A. K. HALVE, DEEPTI BHADAURIA, B. BHASKAR, R. DUBEY AND VASUDHA SHARMA 680-682
- Simultaneous Spectrophotometric Estimation of Atorvastatin Calcium and Ezetimibe in Tablets**
S. S. SONAWANE, A. A. SHIRKHEDKAR, R. A. FURSULE AND S. J. SURANA 683-684
- High Performance Thin Layer Chromatographic Estimation of Lansoprazole and Domperidone in Tablets**
J. V. SUSHEEL, M. LEKHA AND T. K. RAVI 684-686
- Antimicrobial Activity of *Helicteres isora* Root**
S. VENKATESH, K. SAILAXMI, B. MADHAVA REDDY AND MULLANGI RAMESH 687-689
- Synthesis and Antibacterial Activity of 2-phenyl-3,5-diphenyl (substituted) -6-aryl-3,3a,5,6-tetrahydro-2H-pyrazolo[3,4-d]thiazoles**
S. K. SAHU, S. K. MISHRA, R. K. MOHANTA, P. K. PANDA AND MD. AFZAL AZAM 689-692

- Simultaneous Estimation of Aceclofenac, Paracetamol and Chlorzoxazone in Tablets**
G. GARG, SWARNLATA SARAF AND S. SARAF 692-694
- Reverse Phase High Performance Liquid Chromatography Method for Estimation of Ezetimibe in Bulk and Pharmaceutical Formulations**
S. K. AKMAR, LATA KOTHAPALLI, ASHA THOMAS, SUMITRA JANGAM AND A. D. DESHPANDE 695-697
- Synthesis and Antiinflammatory Activity of N-Aryl Anthranilic Acid and its Derivatives**
J. K. JOSHI, V. R. PATEL, K. PATEL, D. RANA, K. SHAH, RONAK PATEL AND RAJESH PATEL 697-699
- RP-HPLC Method for the Determination of Atorvastatin calcium and Nicotinic acid in Combined Tablet Dosage Form**
D. A. SHAH, K. K. BHATT, R. S. MEHTA, M. B. SHANKAR AND S. L. BALDANIA 700-703
- Determination of Etoricoxib in Pharmaceutical Formulations by HPLC Method**
H. M. PATEL, B. N. SUHAGIA, S. A. SHAH AND I. S. RATHOD 703-705

Proceedings of the Symposium on Advances in Pulmonary and Nasal Drug Delivery, October 2007, Mumbai

- Albumin Microspheres of Fluticasone Propionate Inclusion Complexes for Pulmonary Delivery**
A. A. LOHADE, D. J. SINGH, J. J. PARMAR, D. D. HEGDE, M. D. MENON, P. S. SONI, A. SAMAD AND R. V. GAIKWAD 707-709
- Design and Development of Thermoreversible Mucoadhesive Microemulsion for Intranasal Delivery of Sumatriptan Succinate**
R. S. BHANUSHALI AND A. N. BAJAJ 709-712
- Preparation and Characterization of Chitosan Nanoparticles for Nose to Brain Delivery of a Cholinesterase inhibitor**
BHAVNA, V. SHARMA, M. ALI, S. BABOOTA AND J. ALI 712-713
- Poloxamer Coated Fluticasone Propionate Microparticles for Pulmonary Delivery; *In Vivo* Lung Deposition and Efficacy Studies**
D. J. SINGH, J. J. PARMAR, D. D. HEGDE, M. D. MENON, P. S. SONI, A. SAMAD, AND R. V. GAIKWAD 714-715
- Sustained Release Budesonide Liposomes: Lung Deposition and Efficacy Evaluation**
J. J. PARMAR, D. J. SINGH, D. D. HEGDE, M. D. MENON, P. S. SONI, A. SAMAD AND R. V. GAIKWAD 716-717
- Generation of Budesonide Microparticles by Spray Drying Technology for Pulmonary Delivery**
S. R. NAIKWADE AND A. N. BAJAJ 717-721
- Microemulsion of Lamotrigine for Nasal Delivery**
A. J. SHENDE, R. R. PATIL AND P. V. DEVARAJAN 721-722
- Development of a pMDI Formulation Containing Budesonide**
E. ROBINS, G. BROUET AND S. PRIOLKAR 722-724
- Development of a pMDI Formulation Containing Salbutamol**
E. ROBINS, G. WILLIAMS AND S. PRIOLKAR 724-726
- Aqua Triggered *In Situ* Gelling Microemulsion for Nasal Delivery**
R. R. SHELKE AND P. V. DEVARAJAN 726-727
- In vivo* Performance of Nasal Spray Pumps in Human Volunteers By SPECT-CT Imaging**
S. A. HAZARE, M. D. MENON, P. S. SONI, G. WILLIAMS AND G. BROUET 728-729
- Nasal Permeation Enhancement of Sumatriptan Succinate through Nasal Mucosa**
S. S. SHIDHAYE, N. S. SAINDANE, P. V. THAKKAR, S. B. SUTAR AND V. J. KADAM 729-731
- Formulation Development of Eucalyptus Oil Microemulsion for Intranasal Delivery**
N. G. TIWARI AND A. N. BAJAJ 731-733

Generation of Budesonide Microparticles by Spray Drying Technology for Pulmonary Delivery

S. R. NAIKWADE AND A. N. BAJAJ*

C. U. Shah College of Pharmacy, S.N.D.T. Woman's University, Juhu Campus, Santacruz (W), Mumbai - 400 049, India

***For correspondence**

E-mail: bajajamrita@rediffmail.com

Treating respiratory diseases with inhalers requires delivering sufficient drug to the lungs to bring about a therapeutic response. For optimal efficacy, drug administration must be reliable, reproducible and convenient. Enhanced powder dispersibility could be designed into microspheres and porous particles through a combination of novel formulation and process design¹. The present work outlines the design of dry powder inhaler (DPI) formulations to achieve delivery goals. Formulation development, characterization strategies and processing methods have been discussed. Budesonide (BUD) has wide range of inhibitory activities against inflammatory mediators. Conventional BUD DPI formulations were developed and the effect of various grades of inhalable lactose on respirable fraction was studied. BUD microspheres and porous particles were developed using spray drying technology which resulted in improved respirable fraction of BUD.

MATERIALS AND METHODS

Budesonide was obtained from Lupin Ltd., Mumbai; gelatin and chitosan were procured from SD Fine Chemicals, Mumbai and different grades of inhalable lactose were obtained as gift sample from DMV Int., The Netherlands.

Development of conventional BUD DPI formulations:

Drug was mixed with fine lactose and this premix was dispersed over coarse lactose in geometric proportions and developed formulations were characterized (Table 1)². Degree of deacetylation of chitosan was determined by IR spectroscopy³.

Development of microspheres and porous particles by spray drying:

Polymers chitosan, gelatin and their combination were spray dried using a Labultima Mini Spray Dryer. Process parameters were optimized using 2² factorial design. Effect of different parameters was studied (fig. 1). Gelatin /BUD and chitosan/ BUD were spray dried in water: methanol (1:1) as 1.0% and 0.5% w/v, respectively⁴. Porous particles were generated by adding chloroform (5% v/v) as blowing agent⁵. *In vitro* deposition was determined using a Twin Stage Impinger apparatus². Particles were also subjected to Anderson Cascade Impactor studies to determine mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD). DSC studies were performed.




Fig. 1: Comparative in vitro pulmonary deposition pattern of BUD conventional formulations
 -Device; - Stage I; and - Stage II

TABLE 1: QUALITY CONTROL TESTS PERFORMED ON CONVENTIONAL BUD DPI FORMULATIONS

Batch code	Assay (% w/w)	Bulk density (g/cc)	Moisture content (% w/w)	% deposition in stage ii
A	109.6011	0.3333	0.0327	32.0487
B	103.5188	0.68	0.0109	31.6768
C	112.5635	0.3222	0.0020	30.9298
D	106.0086	0.625	0.0040	31.8673
E	108.5848	0.5875	0.0015	30.4080

Batch A contains Lactohale 300 and Pharmatose 150M (60:40); batch B contains Inhalac and Lactohale 100M (60:40); batch C contains Lactohale 300 and Pharmatose 150M (70:30); batch D contains Inhalac and Pharmatose 150M (70:30); batch E contains Inhalac and Lactohale 100 (70:30)

In vitro release studies:

These studies were conducted using Flow Through Cell assembly (USP IV) at 37° with flow rate of 16 ml/min (in 100 ml of phosphate buffer pH 7.0)⁶. Five milliliter sample was analyzed by UV Spectrophotometry at 246 nm. Mechanism of drug release was determined using various kinetic models. Coefficient of correlation from plots of Q vs. t (cumulative % drug release vs. time), log Q vs. log t and Q vs. square root of t were calculated.

RESULTS AND DISCUSSION

BUD DPI formulations were developed using various grades of inhalable lactose like Pharmatose, Lactohale, Inhalac and mannitol in various combinations. The effect of particle size of excipients on respirable fraction of BUD was assessed (Table 1 and fig. 1). Degree of deacetylation of chitosan was found to be 45%. Optimum process parameters were inlet temperature (130°), aspirator rate (50%), feed

TABLE 2: RESULTS OF OPTIMIZED DPI FORMULATIONS PREPARED BY SPRAY DRYING TECHNOLOGY

Parameters	Observations	
	BUD microspheres	BUD porous particles
Appearance	Hollow, porous	Hollow, porous, free flowing microspheres
Particle size	1- 10 μm	1- 10 μm
% yield	20-30	20-30
% moisture content	0.3770	0.3280
% drug entrapment	86.00 (RSD= 0.4890)	96.00 (RSD= 0.2616)
% FPF	35.6785%	46.8199%
MMAD	4.60 μm	4.30 μm
GSD	1.75 μm	2.54 μm

FPF is fine particle fraction; MMAD is mass median aerodynamic diameter and GSD is geometric standard deviation




Fig. 2: Factorial design for optimization of process parameters. (a) Effect of aspirator and feed spray pressure on % yield; (b) Effect of aspirator rate and feed spray pressure on % drug entrapment; (c) Effect of aspirator rate and inlet temperature on moisture content of product

rate (30%) and outlet temperature (80°) (fig. 2). Microspheres and porous particles of BUD were prepared with chitosan (1:2, drug: polymer ratio) with 86% and 96% w/w entrapment efficiency, respectively. Developed chitosan microspheres and porous particles were characterized for particle size (SEM analysis




Fig. 3: SEM micrograph of developed formulations (a) Chitosan microspheres and (b) chitosan porous particles




Fig. 4: DSC spectra of developed formulations (a) BUD porous particles; (b) BUD microspheres; (c) BUD pure; (d) Chitosan pure; (e) BUD conventional formulation

TABLE 3: REGRESSION COEFFICIENTS FOR FORMULATIONS

Formulations	R2		
	Zero order	Korsmeyer-peppas	Matrix
Gelatin microspheres	0.4272	0.9920	0.9166
Chitosan microspheres	0.8338	0.9722	0.9898
Gelatin porous particles	1.0000	1.0000	1.0000
Chitosan porous particles	0.8315	0.9877	0.9906

- JSM- 840A-/WDS/EDS Sys- JEOL instrument, fig. 3), % drug entrapment and % FPF (Table 2). DSC studies confirmed no interaction between drug and polymer (fig. 4). *In vitro* release profile is shown in fig. 5a. Regression coefficients (near to 1) for zero order, matrix and Korsmeyer-Peppas kinetic equations confirmed release by slow zero order kinetics through diffusion matrix (Table 3, fig. 5b and 5c). Korsmeyer-Peppas plot indicated good linearity ($r^2 = 0.9722$).

Microspheres and porous particles were engineered to be both hollow and porous and these exhibited excellent flow and dispersion from passive DPIs. *In vitro* characterization predicted highly efficient lung delivery. The results indicated that spray drying technology can be used to generate inhalable particles like microspheres and porous particles with improved pulmonary deposition as compared to conventional DPI formulations.

REFERENCES

1. Ashurst I, Malton A, Prime D, Sumbly B. Latest advances in the development of dry powder inhalers. *Pharm Sci Tech Today* 2000;3:246-56.
2. Feddah MR, Brown KF, Gibbs EM, Davies NM. *In vitro*






Fig. 5: *In vitro* release profile and release kinetics of formulations a. *In vitro* release profile of microspheres and porous particles prepared by spray drying method; —●— gelatin microspheres; —■— chitosan microspheres; —▲— gelatin porous particles; —◆— chitosan porous particles; (b) Release kinetics of chitosan microspheres; —●— actual; —■— matrix; —▲— Peppas model (c) Release kinetics of porous particles of chitosan; —●— actual; —■— matrix; —▲— Peppas model

characterization of Metered dose inhaler versus dry powder inhaler Glucocorticoid products- influence of inspiratory flow rates. *J Pharm Pharm Sci* 2000;3:317-24.

3. Baxter A, Dillon M, Taylor KD, Roberts GA. Improved method for IR determination of the degree of N-acetylation of chitosan. *Int J Biol Macromol* 1992;14:166-9.
4. Corrigan DO, Healy AM, Corrigan OI. Preparation and release of salbutamol from chitosan and chitosan co-spray dried compacts and

www.ijpsonline.com

multiparticulates. Eur J Pharm Biopharm 2006;62:295-305.

aerosol inhaler products. Int J Pharm 2003;255:175-87.

5. He P, Davis SS, Illum L. Chitosan microspheres prepared by spray drying. Int J Pharm 1999;187:53-65.

6. Davies NM, Feddah MR, A novel method for assessing dissolution of

25 October, 2007

Indian J. Pharm. Sci., 2007, 69 (5): 717-721
